相关实验视频

Updated: Jul 26, 2025

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

在不寻常的地点开发和验证与血栓塞缩综合征 (TTS) 发生血栓塞的算法

Shayan Hobbi^1,2, Patrick Saunders-Hastings³, Cindy Ke Zhou⁴

¹IBM Consulting, Bethesda, MD, USA.

International journal of general medicine

|June 21, 2023

概括

使用ICD-10-CM代码的新算法准确地识别了COVID-19疫苗接种后的血栓塞综合征 (TTS) 的血栓塞. 这种经过验证的工具有助于监测疫苗和其他医疗产品的安全性.

科学领域:

医疗信息学医疗信息学
药物监督药物监督药物监督
临床编码临床编码

背景情况:

血栓塞栓症候群 (TTS) 的血栓形成是一种罕见但严重的不良事件,与基于腺病毒载体的COVID-19疫苗有关.
准确识别TTS病例对于疫苗安全监测至关重要.
使用国际疾病分类-10-临床修改 (ICD-10-CM) 代码识别TTS的现有方法缺乏对不寻常地点的验证研究.

研究的目的:

开发和验证基于ICD-10-CM的算法,用于识别不寻常的网站TTS.
评估算法的性能与布莱顿协作案例定义相比.
为了支持美国食品和药物管理局 (FDA) 的生物制品有效性和安全 (BEST) 倡议.

主要方法:

利用文献审查和临床输入创建一个ICD-10-CM算法不寻常的网站TTS.
在电子健康记录 (EHR) 系统中对实验室,病理学和成像报告进行算法的验证.
使用病理学或成像作为黄金标准,计算出具有95%置信区间 (95% CI) 的正预测值 (PPV).

主要成果:

该算法发现了278个不寻常的TTS病例,其中117个得到了验证.
异常位置TTS的积极预测值 (PPV) 为76.1% (95% CI 67.2-83.2%).
血小板缺血的PPV高达98.3% (95% CI 92.1-99.5%). 血小板缺血的PPV高达98.3% (95% CI 92.1-99.5%). 血小板缺血的PPV高达98.3% (95% CI 92.1-99.5%).

结论:

这项研究报告了首个经过验证的ICD-10-CM算法用于不寻常的网站TTS.
该算法展示了中等到高的PPV,适合观察性研究.
经过验证的算法可用于对COVID-19疫苗和其他医疗产品的积极监测.

关键词:

在 COVID-19 疫情中,这就是TTSTTS.电子健康记录是电子健康记录.血栓形成与血栓细胞减小综合征.验证验证的时间

更多相关视频

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

相关概念视频

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...